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Background: Despite several investigations, findings on weight changes during
and after adjuvant treatment for breast cancer are diverse and point in several
directions. Objective: The aims of this study were to investigate changes in weight
and body composition associated with contemporary anticancer medication and to
examine factors that might influence the assessment and diversity of the findings.
Methods: This article used the method of a scoping review to map the body of
literature. From searching the databases PubMed, CINAHL, and EMBASE using
MeSH terms, CINAHL terms, and Emtree, as well as free text, 19 articles were
selected for further investigation. Results: The scoping review illustrates how
findings in weight and body composition changes fluctuate over time as illustrated in
4 measure points: short term, 1year, 18months/2years, and long term. The studies
displayed differences regarding study designs, sample sizes, treatment regimens,
measure points and techniques, and cutoff values for assessing weight changes,
which make it difficult to synthesize findings and provide strong evidence for use in
clinical practice. Conclusion: Synthesizing findings over time illustrates the need
for attention on younger premenopausal women given chemotherapy. Weight need
to be monitored for at least 2years as short-term changes may be caused by
increased body water, whereas long-term changes seem to be related with increased
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fat mass essential for risking recurrence and early death. Implications for
Practice: The diversity in methods discloses the need for the research community to
reach consensus regarding study designs for future research in this area.
T
he purpose of a scoping review is to map existing literature
on a certain topic that may be of complex or heteroge-
neous nature and describe the volume, nature, and char-
acteristics of the primary research.1 Thus, a scoping review aims to
present an overview of a potentially large and diverse body of liter-
ature. This scoping review focuses on weight changes during and
after antineoplastic treatment for breast cancer (BC). This are of
concern because of the association between fat tissue, BC de-
velopment, and the increased risk of both recurrence and early death
found among breast cancer stricken women with relative weight
variations of 5%.2
Weight changes in women with BC have been investigated for
decades.2Y10 Studies have found that women in current adjuvant
chemotherapy (CT) for BC on average gain 2.0kg during and after
adjuvant treatment, and weight gain up to 10.0kg is not uncom-
mon.5 A main contributor to weight gain is suggested to be the
durationofCT.6Y8,10,11 However, with current antineoplasticagents,
for example, anthracycline-based CT (anthracy-CT), weight changes
may be overestimated.12 Nevertheless, Makari-Judson et al13
found weight gain ranging from 1.6kg at 1year to 6.0kg at
2years. Adjuvant cancer treatment involves radiotherapy, as well
as CT, and endocrine treatment (ET).14 Some researchers point at
ET and menopause status as a contributing factor. For example,
Goodwin et al4 and Ganz11 found onset of menopause and CT
contributed to weight gain. Yet, findings are inconclusive as some
studies suggest premenopausal status to be a predictor,3,8,9 whereas
others claim that menopausal status does not influence weight
gain.5,15,16 Recently, a review identified the effect of ET on weight
gain including studies that compared estrogen receptor antagonist
(ERA), aromatase inhibitors (AIs), and placebo.17 Although there
was no significant difference between the groups, the authors pointed
at inconsistent results and the need for further investigations.
Despite investigations for years, findings on weight changes during
and after adjuvant treatment for BC are diverse. Thus, the aims of
this scoping review was to investigate changes in weight associated
with contemporary anticancer medication and examine factors
that might influence the assessment and diversity of the findings.
n Materials and Methods
This scoping review was conducted by a research team consisting
of health professionals with clinical and research experience. With
inspiration from the original framework by Arksey and O"Malley,1
the review consisted of 5 steps: identify the research question;
find relevant studies; select the studies relevant for the study;
chart the data; and collate, summarize, and report the results.
The Research Question
Our research question was: What is known from the existing
literature about the extent and patterns of changes in weight
among women during and after current adjuvant standard
antineoplastic treatment for BC?
Find and Select Relevant Studies
The literature search was conducted in collaboration with a li-
brarian from a university hospital. Although scoping reviews tend
to comprehensively search all unpublished and published studies,
we selected only published studies sought by means of databases.
The literature search was conducted in PubMed, CINAHL, and
EMBASE using MeSH terms, CINAHL terms, and Emtree, as
well as free text not to exclude relevant literature in the databases
search (Table 1). The search in PubMed provided most articles,
and the search string from PubMed is shown in Table 2. The
titles were initially screened and included for further investigation if
they seemed to be relevant to the topic. Review articles and articles
without abstract were excluded. During further screenings of ab-
stracts and full-text readings, primary research focusing on women
with BC receiving antineoplastic treatment with anthracy-CT
and/or endocrine therapy and weight changes was included.
Weight changes have been described in different terms. Thus,
we included studies that reported relative weight changes
(percent), absolute changes (in kilograms) and body mass index,
and body composition terms (fat mass, fat-free mass, and total
body water). A flowchart illustrates the selection process of the
included studies investigating the associations between weight
changes and treatment with anthracy-CTTET or ET as a standalone
treatment (Figure).
Chart the Data, Collate, and Summarize
A matrix charting detailing information of data was developed
and consulted with the research team. The first author, who was
familiar with the data in its entirety, extracted and categorized the
data. Study design, aim, sample size, treatment, measure points,
technique, and cutoff are charted in Table 3 and briefly reported
narratively in the text. Subsequently, the specific findings were
collated and summarized narratively using a thematic construc-
tion regarding weight changes divided into 4 follow-up periods:
short-term, after 1year, after 18months/2years, and after more
than 2years (Table 4). Scoping reviews have recently been meth-
odologically developed to also contain a step for ‘‘synthesizing
findings.’’33,34 As such, the findings are continuously synthe-
sized. The optional consultation exercise described by Arksey and
O"Malley1 was not conducted. However, 2 members of the research
team, who are considered clinical experts, verified the relevance of
the findings. In accordance with the purpose of scoping reviews,
we did not appraise the quality of data extracted before inclusion.
n Results
The review reports findings from 19 studies published from 2004
to 2017 (Table 3). Assessing studies published from 2004 and
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onward, 2 studies report changes in weight associated with ET as
the main focus.20,30 Four studies report findings on CT,19,23Y25
and 13 studies, reporting findings on CT, included the effect
of ET.6,7,10,12,18,21,22,26Y29,31,32
n Characteristics of Study Design and
Data Collection
The studies were conducted almost worldwide displaying find-
ings from Europe (5), North and South America (6 and 2), and
Asia (6).
The majority of the studies had a retrospective
design6,10,23Y32 and examined BC stages I to III.6,10,23,24,28
Most of the studies included between 100 and 350
participants, and 2 included more than 3000 women.6,27 In
several studies, the methods used to estimate weight changes
were not described10,24,26,29,31,32 or did not specify the exact
CT regimens.27,32 If the regimens were specified, the women
received various regimens,6,10,23Y26,28,29,31 and the descriptions of
ET differed. In most studies, ET followed CT. However, in
addition to the retrospective study focusing on ET,30 ET was also
given as a standalone treatment and reported separately in 3
studies.6,10,31 Cutoff points for assessing weight changes were
either missing23,28,30 or defined as absolute weight changes
ranging from 1.0 to 2.5kg,24,27,30Y32 relative weight changes of
T5%,6,25,29,31 or as the difference between measurements.10,31
Of 7 studies with a prospective design,7,12,18Y22 5 included
women with BC in stages I to III,18Y22 and 2 included women in
stages I to II.7,12 The samples consisted of 20 to 272 women,
and follow-up time varied from completed CT (approximately
4Y6months) and up to 2years. Most studies ended measure-
ment after 1year.7,18Y20 Chemotherapy regimens were specified
in 6 studies,7,12,18Y22 and one study reported findings from ET
Table 1 & Key Words for Databases Searching
Updated January 2017 PubMed (1014 Entries) CINAHL (226 Entries EMBASE (1831 Entries)
Breast neoplasms MeSH CINAHL Headings Emtree
Breast neoplasms Breast neoplasms Breast cancer
Free text: Free text: Free text:
Breast neoplasms Breast neoplasms Breast neoplasms
Breast cancer Breast cancer Breast cancer
Body weight MeSH CINAHL Headings Emtree
Body weight Body weight Body weight
changes Body weight changes Weight change
Weight gain Weight gain Weight gain
Weight loss Weight loss Weight reduction
Overweight Obesity Obesity
Obesity
Free text: Free text: Free text:
Weight loss Weight loss Weight loss
Weight reduction Weight reduction Weight reduction
Weight gain Weight gain Weight gain




Adjuvant treatment MeSH CINAHL Headings Emtree
Chemotherapy, adjuvant Chemotherapy, adjuvant Adjuvant chemotherapy
Antineoplastic agents Antineoplastic agents Antineoplastic agent
Aromatase inhibitors Aromatase inhibitors Aromatase inhibitor
Estrogen antagonists Estrogen antagonists Antiestrogen
Free text: Free text: Free text:
Chemotherapy Chemotherapy Chemotherapy
Antineoplastic agent Antineoplastic agent Antineoplastic agent
Aromatase inhibitors Aromatase inhibitors Aromatase inhibitors
Estrogen antagonists Estrogen antagonists Estrogen antagonists
Table 2 & Search Strategy PubMed
((WBreast NeoplasmsW[Mesh] OR breast neoplasms[tw] OR breast cancer[tw]) AND (((((((((((WBody WeightW[Mesh] OR WBody Weight
ChangesW[Mesh]) OR WWeight GainW[Mesh]) OR WWeight LossW[Mesh]) OR weight loss[tw]) OR weight reduction[tw]) OR weight
gain[tw]) OR WOverweightW[Mesh]) OR WObesityW[Mesh]) OR (weight change[tw] OR weight changes[tw])) OR overweight[tw]) OR
(obesity[tw] OR obese[tw]))) AND (((((((WChemotherapy, AdjuvantW[Mesh] OR WAntineoplastic AgentsW[Mesh]) OR WAromatase
InhibitorsW[Mesh]) OR WEstrogen AntagonistsW[Mesh]) OR chemotherapy[tw]) OR antineoplastic agent[tw]) OR aromatase
inhibitors[tw]) OR Estrogen Antagonists[tw])
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alone.20 If cutoff points for assessing weight changes were de-
scribed, they were defined as absolute weight changes of T2.5kg12
and relative changes of T2.4%21 or T5%.19 One study applying
a retrospective and prospective design included approximately
6000 women, but attrition was 2000 women at the 3-year
follow-up.32
n Reviewing and Synthesizing Findings
in a Time Perspective
Short-term Follow-up
Reviewing the articles and synthesizing findings from baseline
until 10months after baseline showed that 13 of the studies
reported weight changes short term.10,12,18Y25,28,29,32 The
changes in weight and body composition were mainly related
to CT except in the study of Francini et al.20 In addition, ET was
reported as a standalone treatment in the studies of Pedersen
et al21 and Basaran et al.10 In the last case, there were only 5
persons in this group; thus, these findings are omitted from this
review.
Francini et al20 evaluated the changes in body composition
among postmenopausal women that changed treatment from
ERA to AI. They found decreasing weight and fat mass in the
AI group and decreasing weight and stable fat mass in the ERA
group. The differences were not statistically significant from base-
line. However, the changes reported by Pedersen et al21 among
mainly postmenopausal receiving AI displayed no changes in
weight or fat mass. Thus, studies reporting short-term follow-up
on ET seem not to provide a common direction.
Changes related to CT showed a mean or median weight
gain ranging from 1.0kg to 4.2kg12,19,21,22,25,29,32 or a relative
weight gain ranging from 2.2% to 7.4%.10,22,32 Although all
included studies applied anthracy-CT, the CT regimens could
vary in lengths and numbers of drugs, and some reported find-
ings in a mixed group including nonYanthracy-CT.
The unclear findings associated with short-term ET are also
manifest with respect to changes in weight and body composition
after CT. For example, Han et al28 reported stable weight but
Figure n Flowchart selection process.
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Table 3 & Characteristics of Study Design and Data Collection
Authors Design, Purpose
Sample Size,
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Table 3 & Characteristics of Study Design and Data Collection, Continued
Authors Design, Purpose
Sample Size,




Vargas-Meza et al25 To analyze changes in the
patients" (breast cancer
women"s) body weight
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without body composition data. These details were shown in
Freedman and colleagues"18 study, which found a minimally
increased weight of 0.27T4.6kg (P= .85) at 10months, but a sta-
tistically significant (P=.03) decrease in fat-free mass. Fluctua-
tion in body composition may thus appear despite stable weight.
On the contrary, Ingram and Brown12 and Pedersen et al21
found a larger mean weight gain (1.4 and 1.6kg, respectively) with
an increase in fat-free mass among women given AC (adriamycin,
cyclophosphamide)12 or AC-T (adriamycin, cyclophosphamide,
taxanes) (PG .0001)21 apparently caused by water retention. In the
last case, the women were mainly premenopausal. On the other
hand, increasing fat mass was found in a mixed group given CEF
(cyclophosphamide, epirubicin, fluorouracil) or CMF (cyclophos-
phamide, methotrexate, fluorouracil),12 which was suggested to be
caused by the longer duration of treatment with CEF and CMF.12
AC treatment has a shorter duration than CEF, CMF, or
AC-T, and the duration of CT as a main factor for weight gain is
supported by the study of Ricci et al.23 They found that spe-
cifically AC-T regimens had the highest risk of weight gain
1month after completing CT compared with other regimens.
The body mass index changes from 27.4kg/m2 to 28.3kg/m2
(PG .001). The women in the AC-T group were younger
(54.2T11years) than women in the other regimens (59.3T
11.2years) (P=.007).23 In this case, it is unknown whether the
changes consist of increased body water.
As opposed to Ricci et al,23 Vargas-Meza et al25 found no
differences in weight whether the regimens were anthracycline
based or not. In their study of 200 women, 155 women gained
weight, of whom 41 gained between 6% and 10%, and 19 gained
more than 10%.25 Thus, 60 women had serious weight gain of
concern for survival and recurrence. Although the weight did
not differ between premenopausal and postmenopausal women, a
higher percent of premenopausal women gained weight. Finally,
Wang et al24 found an even distribution in stable weight, weight
gain, and weight loss. They point at young age at diagnosis
(P=.028) and the duration of CT (P=.037) as contributing fac-
tors for weight gain, whereas there was no correlation between
menopause and weight.
Synthesizing these short-term findings, weight gain after CT is
common and may exceed 5% relative weight gain of concern for
recurrence and survival. As few studies report body composition
changes, it is difficult to provide a common picture of the pattern of
the changes in the short term. However, weight gain may be
associated with increased fat-free mass due to water retention or
increased fat mass due to longer duration of CT. Treatment with
ET alone seems to point in different directions showing decreasing
weight and fat mass in postmenopausal women given AI or no
changes among primarily postmenopausal women given AI.
One-Year Follow-up
Nine studies reported findings at 1-year follow-up.7,10,19Y21,
26,28,29,31 The pattern of the changes was centered on weight
gain as the main result during and after CT.7,10,19,21,26,31 The
mean weight gain ranged from 0.9 to 3.9kg,19,21,31 and rela-
tive weight gain ranged from 0.39% to 5.9%.10,19,26 In some
studies, the amount of women gaining weight increased com-
pared with short-term measurement. Basaran et al10 reported
an increase from 67% to 72%. Similarly, Tredan et al19 showed
a difference from 52.1% to 59.7% in a cohort of 272 women,
of whom 233 were given anthracy-CT. Forty percent of those
who gained weight increased their weight by more than 5% in
the short term, increasing to 45% at 1year. Although Chaudhary
et al26 report a minimal mean weight gain of 0.39%, they found
a statistically significant difference when they investigated asso-
ciations between menopause status and tumor stages.
Body composition changes showed a tendency toward increas-
ing fat mass and decreasing fat-free mass.7,21 Gordon et al7 found
increased fat mass, especially in the trunk in their study of
43 premenopausal women in different treatment regimens. The
Table 3 & Characteristics of Study Design and Data Collection, Continued
Authors Design, Purpose
Sample Size,




Heideman et al31 Exploring the frequency







T ET, or no
medication
At diagnosis, and





Gu et al32 To investigate weight
patterns 6, 18, and
36 mo after diagnosis
and potential
socio-demographic and






One year before and
at diagnosis
(self-reported), and





Abbreviations: AC, adriamycin, cyclophosphamide; AI, aromatase inhibitor; anthracy-CT, anthracycline based chemotherapy; BC, breast cancer; BIA,
bioelectrical impedance analysis; BMI, body mass index; CEF, cyclophosphamide, epirubicin, fluorouracil; CMF, cyclophosphamide, methotrexate, fluorouracil;
CT, chemotherapy; DXA, dual-energy x-ray absorptiometry; ERA, estrogen receptor antagonist; ET, endocrine therapy; RT, radiotherapy; TAC, taxanes,
adriamycin, cyclophosphamide; WC, weight changes; WG, weight gain.
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data were unified and calculated for the whole group. Thus, the
analysis does not account for changes in women given anthracy-
CT, who provided only one-third of the data.
Heideman et al31 calculated weight changes in groups receiv-
ing no treatment, CT alone, CT T ET, or ET alone. They found
weight gain in all groups with the highest gain when receiving
CT T ET. This is contradictory to the findings of Jeon et al29
and Han et al,28 who reported stable weight at 12months. In
addition, Han et al28 found weight loss of 1.17kg among
women who did not receive ET. These findings suggest that
treatment with ET impacts weight development but ambigu-
ously. For example, weight increased among women given ET
alone,31 whereas changes in weight and fat mass associated
with ET alone was found stable at 1year in another study.21
Investigating the difference between ERA and AI, weight
among women receiving ERA remained stable, whereas weight
and fat mass decreased in the group receiving AI.20
Synthesizing findings at 1year, weight tended to increase from
baseline among women given CT partly as increasing fat mass.
The effect of CT still seems essential as CT alone or followed by
ET may lead to increasing weight. However, the findings lack
unequivocalness as weight was found to be stable or decreased
when CT was given alone. Thus, the effect of ET on weight at
1-year follow-up seems ambiguous pointing at weight gain, stable
weight, and weight loss.
Eighteen-Month to 2-Year Follow-up
Seven studies reported findings in the time span from 18 to
24months.21,22,27Y30,32 Weight gain as the main result during and
after CT ranged from 0.7 to 2.6kg.21,22,32 According to Pedersen
et al,21 the women had an average gain of 1.4kg consisting of
increased fat mass (P=.007). Chen et al27 reported a mean weight
gain of 1.7kg, and with a cutoff of 2 kilos, 61% gained weight,
14% lost weight, and 25% had no weight change. In the weight
gain group, 37% gained 5% or greater, and 17% gained more
than 10%. These findings were associated with young age and
being premenopausal.27 In support of these findings, Gu et al32
demonstrated a median weight gain of 2.0kg showing that 33%
had weight gain of 5% or greater. Gu et al32 and Chen et al27
reported findings from anthracy-CT, whereas Liu et al22 reported
relative weight changes divided into anthracy-CT and nonY
anthracy-CT. They found that anthracy-CT regimens showed a
slower and milder increase compared with other chemothera-
peutic regimens and the highest changes among women in nonY
anthracy-CT (mean, 2.6kg [4.7%]) compared with anthracy-CT
(mean, 0.7kg; 1.2%).
Although Heideman et al31 claimed that a majority of women
receiving CT T ET displayed weight gain, stable weight was
present in the studies of Han et al28 and Jeon et al.29 Weight
also remained stable at 18months among the women receiving
ET (majority AI) alone in the study of Pedersen et al.21 How-
ever, Nyrop et al30 illustrated that weight changes at 24months
after initial CT involve almost an equal division in weight gain,
stable weight, and weight loss. Weight gain in the 39% women
was especially noted among women given CT and was not asso-
ciated with the kind of ET given.
Synthesizing the findings in the time span 18 to 24months
from diagnosis, weight gain appeared commonly and in some cases
reported to exceed 5% relative weight gain among a majority of
women. The difference between anthracy-CT and nonYanthracy-
CT with or without ET is not clear. More studies reported stable
weight or approximately the same amount of weight gain among
women in anthracy-CT than in women receiving nonYanthracy-CT.
No changes appeared when ET was given alone, and a possible
weight gain was associated only with CT and not the kind of ET.
Long-term Follow-upVMore Than 2Years
Three studies reported findings in the time span more than
2years.6,31,32 Examining the association between different CT
regimens, ERA use, and weight gain, Saquib et al6 found sig-
nificant weight gain Q 5%. All types of CT were significantly
associated with weight gain (odds ratio, 1.65; 95% confidence
interval, 1.12Y2.43) as opposed to ERA (odds ratio, 1.03; 95%
confidence interval, 0.71Y1.51).
Heideman et al31 found a mean weight gain of 2.4kg in the
total group. Weight in the no-treatment group appeared stable.
A minimal increase in ET-only group (mean, 0.9kg) was found,
and the highest weight gain among women given CT or CT+ET
of 2.9 and 4.7kg, respectively. The last group displayed the largest
weight gain at 5years as 46.9% gained more than 5% mean 4.7kg
(SD 6.3; PG.05). No significant changes were found among
women receiving ET alone. Although Gu et al32 at this time
span found decreasing median weight gain equivalent to 1.0 kg
compared with 18months" measurement, 33% of the women
still had weight gain of 5% or greater that was associated with
being younger, being premenopausal, and receiving CT.
Synthesizing long-term findings shows how women, initially
treated with CT, suffer from persistent serious weight gain in the
long term compared with baseline. Endocrine therapy induces
none or minimal long-term weight.
REVIEWING AND SYNTHESIZING OTHER CONTRIBUTING
FACTORS FOR WEIGHT GAIN THAN TREATMENT
In this review, contributing factors for especially weight gain were
reported and discussed. A central topic was menopause status, and
especially premenopause seems to be an essential topic for further
investigation.23 Although menopause status was suggested not to
influence weight,25 this review showed that independent of time
span, being premenopausal seems to induce weight gain.10,21,
26,27,31,32 In addition, premature menopause needs to be ob-
served as a contributing factor that may influence body compo-
sition changes.7 Related to this, age, especially being young, may
be a crucial factor.10,21,27,32 Besides this dominant topic, other
contributing factors for weight changes such as comorbidity,10,27
daily caloric intake,25 lifestyle,27,28 prediagnostic weight,27,32 and
disease stage were found.26,27,30
n Discussion
This scoping review reports findings from 19 articles identified
through a systematic literature search. The review demonstrated
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a diversity of studies regarding changes in weight that might
influence the possibility of making synthesis and thus providing
useful recommendation for practitioners. In addition, the article
has shed light over factors that might influence the assessment
and diversity of the findings.
The review shows that several studies have investigated
changes in weight, while fewer included body composition mea-
surements.7,12,18,20,21 In general, the studies display different
treatment modalities, the sample sizes in the retrospective studies
suffer from dropout, and the prospective studies from small
samples. In addition, weight may be self-reported and on dif-
ferent scales if mentioned at all. Although the studies selected for
review investigated modern/third-generation chemotherapeutic
agents, the specific modalities were not described in all cases.
Thus, due to differences regarding study designs, sample sizes,
treatment regimens, measure points, and techniques, the option
for a clear picture of the changes is troublesome. The same limi-
tations appear in a review on weight changes during adjuvant
ET (alone) conducted by Nyrop et al.30 Investigating 38 studies,
they reported that most studies showed no significant difference
whether ET was compared with placebo or AI was compared
with ERA. However, because of methodological issues, they
were not able to draw a firm conclusion, and they recommend
further studies.
Research has focused on weight gain as a contributing factor
to recurrence and decreased survival among women treated
for BC.5Y8,10 Thivat et al2 point at a weight variation of
more than 5% from diagnosis to completed CT as having a
negative impact on recurrence and survival assessed during a
20-year follow-up. Furthermore, a relative weight loss of 2.4%
may have influenced the survival rate among a mixed group of
cancer patients, including women with BC.35 In both studies,
women with stages I to IV BC participated. Stage IV BC is
characterized by distant metastases and a severe prognosis that
may have influenced the findings. Although some studies in this
present review apply a 5% cutoff,6,19,25,29,32 it may be difficult
to evaluate whether the changes in general are more or less than
the serious relative changes crucial for recurrence and survival,
when most studies apply no cutoff or use factual kilos as cutoff
values.7,10,12,18,20Y24,26Y28,30,31
In assessing the studies across, it seems that anthracy-CT regi-
mens given in combination with other chemotherapeutic agents
are essential for weight gain due to the duration of the treat-
ment.12,21,23 Whether the women received ET as follow-up treat-
ment seems not to influence these findings.6,30 The duration of
CT as a main factor and the lack of influence from ET cor-
respond with the findings of Vance et al.8 In this review, they
included studies from 1997 up to 2009 and did not describe the
specific CT regimens. Thus, an unknown amount of studies may
report findings from former regimens and not anthracy-CT.
However, the risk of weight gain needs attention as recently the
Danish Breast Cancer Group14 recommended additional series of
taxanes in BC treatment, which may increase the risk of weight
gain in the future due to prolonged duration.
In addition, it appears that most studies agree about the risk
for weight gain among younger premenopausal women.7,21,23Y27
Although the average weight gain and the association with being
young and premenopausal are supported in other studies,8 the
samples consist of women in different stages: I to II,7 I to III,
and21,23,24 0 to IV,26,27 which may influence the findings.
Weight changes after completing CT up to 1year seem criti-
cal,6,10,12,19,21,22,28,29,31 as more studies reported statistically
significant weight gain at this measure point.21,26,29 Still, after
completed CT, weight gain may consist of water retention that
disappears over time.12,21 Nevertheless, some studies demon-
strate no changes at 1year,28,29 while others claim persistent
weight gain.10,19,31 In some studies, the weight continues to
rise or does not return to baseline weight,6,21,22,31 whereas others
conclude no changes at the 2-year follow-up.28,29 Sheean et al36
also described this diversity of findings. In contrast to the 2 studies
in the present scoping review showing increased weight and
decreased fat mass due to increased body water short term,
they point at stable or increased fat mass after completed CT. The
tendency of increasing fat mass appeared also at later measure
points such as 1-, 2-, and 3-y follow-up. However, in this review,
there was no description of the specific CT regimens.
Limitations
Only studies from database searching in English or Nordic
language were included in this review. Although these limits
may have excluded potential relevant literature, we anticipated
that this specific topic regarding changes in weight during and
after current standard adjuvant antineoplastic treatment for BC
would be covered in scientific databases. We were inspired by
Arksey and O"Malley"s1 original framework for scoping reviews
and followed their recommendations and additionally included
synthesizing, as there is an increasing attention on synthesizing
and using scoping review for clinical recommendations.33,34
Despite this, our scoping review must be used with caution
due of the diversity in study designs and findings.
n Conclusion
This scoping review illustrates how findings in weight and body
composition changes fluctuate over time and vary dependent on
measure points. In addition, the studies apply different cutoffs,
which make it difficult to evaluate the changes in relation to the
serious relative changes crucial for recurrence and survival. The
diversity impacts the synthetization of findings and the possibility
to provide clinicians with evidence-based knowledge to use when
providing information to women with BC.
Despite these difficulties, synthesizing findings over time illus-
trates the need for attention on younger premenopausal women
given CT. To gain more knowledge about the exact changes in
weight and body composition, monitoring these variables for
at least 2years may be essential as short-term changes may be
caused by increased body water, whilst long-term changes seem
to be related with increased fat mass.
Based on this review, we recommend further investigations
applying long-term prospective designs, measurements at cer-
tain time points, and assessing weight and body composition
changes via the same kind of device. For example, bioelectrical
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impedance analysis that is cheap and easy to use could help to
standardize measurement. In addition, to show the patterns
of weight loss, stable weight, and weight gain requires inclusion
of women given the same antineoplastic treatment in relevant
numbers for statistical analysis and using the same cutoff, for
example, 5%.
Given the association between weight gain and risk for re-
currence and increased mortality,2,37 developing evidence-based
knowledge on weight changes during antineoplastic treatment
for BC is important. Moreover, weight changes may influence
the women"s perception of their bodies38 and quality of life,
although mean weight gain may be assessed as modest.39 Thus,
future research may focus on changes in body weight including
body composition among women treated for BC as well as the
women"s experiences of the changes.
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